SLC5A2 and heart failure: Unlike diuretics that resulted in immediate and sustained BP reduction, the BP-lowing effect of SGLT2 inhibition in individuals with heart failure was minimal and transient, thus implying that the clinical benefit might stem from the anatomical and functional remodeling of the cardiovascular system secondary to other pleiotropic effects.